An open label study of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of mild to moderate acne keloidalis.

Author(s): Callender VD, Young CM, Haverstock CL, Carroll CL, Feldman SR

Affiliation(s): Callender Skin & Laser Center, 12164 Central Ave, Suite 225, Mitchellville, MD 20721, USA. drcallender@callenderskin.com

Publication date & source: 2005-06, Cutis., 75(6):317-21.

Publication type: Clinical Trial

Acne keloidalis (AK) is a disease affecting primarily African American men. Topical steroids are a widely accepted treatment of AK; however, no studies have been published investigating their effectiveness. The purpose of this open-label study was to assess the efficacy and tolerability of clobetasol propionate 0.05% and betamethasone valerate 0.12% foams in the treatment of AK in 20 African American patients. These patients were treated for 8 to 12 weeks using a pulsed-dose regimen. We found topical clobetasol propionate foam to be effective in improving AK, and our patients found the foam vehicle to be cosmetically acceptable.